Although numerous clinical trials have demonstrated the efficacy and tolerability of erythropoiesisstimulating agents (ESAs) in patients with chemotherapy-induced anemia (CIA), results of some recent trials and one meta-analysis have suggested that ESAs may negatively impact survival and/or disease control in patients with cancer.
INTRODUCTION
The clinical effectiveness of erythropoiesis-stimulating agents (ESAs) for improving hemoglobin concentrations and reducing the need for RBC transfusions in patients with chemotherapy-induced anemia (CIA) has been repeatedly demonstrated. [1] [2] [3] [4] [5] [6] Data from numerous placebo-controlled clinical trials [4] [5] [6] [7] [8] [9] [10] [11] [12] and meta-analyses [13] [14] [15] [16] have demonstrated that ESAs are generally well tolerated in patients with CIA. However, results of some trials [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and one meta-analysis 27 have suggested that ESAs negatively impact survival and/or disease control in patients with cancer. Of the eight clinical trials noted in the product labels for the ESAs marketed in the United States, four trials were in patients receiving chemotherapy, 19, 22, 24, 25 two trials were in the nonapproved setting of radiotherapy 18, 21 (all six studies targeted hemoglobin levels greater than those currently recommended), and two trials were in the nonapproved setting of patients with advanced cancer not receiving chemotherapy or radiotherapy. 17, 20 In 2008, the product labels for ESAs were updated with a boxed warning highlighting potential safety risks. 28, 29 The association between ESA use and an increased risk of cardiovascular/thromboembolic events has been quantified in multiple placebocontrolled studies, has remained stable over time, and is documented in ESA product labels. A published meta-analysis confirmed the increased risk of thromboembolic events in patients with cancer treated with an ESA versus no ESA (relative risk [RR] ϭ 1.67; 95% CI, 1.35 to 2.06; 35 trials, 6,769 patients). 13 Despite this increased risk, however, ESAs did not increase mortality in this patient population (hazard ratio [HR] ϭ 1.08; 95% CI, 0.99 to 1.18; 42 trials, 8,167 patients). 13 To reassess the benefits and risks of ESAs in the currently approved indication of CIA, we conducted the first pooled analysis of individual patient data from all randomized, placebo-controlled clinical trials of darbepoetin alfa (DA). Analyzing individual patient data provides the ability to standardize the definition of end points to reduce heterogeneity across trials, analyze data with time-to-event methodology, and explore baseline patient characteristics that might predict outcome. Analysis of large numbers of patients also allows detection of smaller differences between treatment groups that may not otherwise be observed among individual studies. We evaluated the effect of DA versus placebo on safety outcomes and transfusions as well as the effect of baseline hemoglobin, hemoglobin events (hemoglobin achieved and hemoglobin rate of increase), and transfusions on safety outcomes.
METHODS

Study Inclusion
All six studies included in this analysis were completed, randomized, blinded, placebo-controlled studies in which DA was administered subcutaneously to patients with nonmyeloid tumors receiving concomitant chemotherapy (Table 1) . With the exception of the small-cell lung cancer trial, 12 all patients received one or more cycles of chemotherapy, had baseline hemoglobin Յ 11 g/dL, and were scheduled to receive future chemotherapy (with or without radiotherapy). In the small-cell lung cancer trial, 12 patients had baseline hemoglobin Ն 9 g/dL and Յ 13 g/dL and received their first dose of chemotherapy and DA simultaneously. DA was withheld if hemoglobin increased more than 14 g/dL for women or more than 15 g/dL for men; however, in the trials published by Pirker et al (2007) 12 and Taylor et al (2005), 7 DA was withheld if hemoglobin increased more than 14 g/dL and more than 13 g/dL, respectively, irrespective of sex.
End Points
Safety end points included overall survival, progression-free survival, and disease progression during treatment and in long-term follow-up and deaths and incidence of adverse events of interest (events identified resulting from known or hypothesized safety concerns) during treatment.
Deaths were identified from (1) reasons given for discontinuation of study drug or study, (2) a reported fatal adverse event; or (3) the long-term follow-up case report form. Except for the small-cell lung cancer trial, 12 collection of disease progression data was not prespecified; therefore, caution should be used when interpreting the progression-based end points. Disease progression was identified if (1) the reason for discontinuing study drug/study was reported as disease progression, (2) end-of-study disease status was progressive disease, or (3) disease progression was noted on the long-term follow-up case report form. If disease progression was not noted, patients were censored at end of study or last long-term follow-up assessment. Time-todisease progression was based on the earliest date that disease progression was reported; progression-free survival time was based on date of progression or date of death, whichever was earlier. Adverse event data were coded using MedDRA, version 9. A prespecified list of preferred terms was used to identify adverse events of interest (cardiovascular/thromboembolic events, seizures, and hypertension). Adverse events were selected without regard to severity of event and reported relationship to investigational product.
RBC Transfusions
The incidence of one or more transfusion was measured from week 5 to the end of treatment phase.
Statistical Methods
Safety and efficacy end points were analyzed using all randomly assigned patients who received one or more dose of investigational product. Patients were analyzed by randomized treatment group (patients randomly assigned into different DA dose groups within a study were treated as a single DA group); studies that allowed patients randomly assigned to placebo to crossover to DA were truncated to the double-blind treatment for analysis purposes. Data were analyzed using SAS version 9 (SAS Institute, Cary, NC).
Baseline demographics and clinical characteristics were summarized by number and percentage for categoric variables and mean (standard deviation) for continuous variables. Kaplan-Meier survival curves were created for overall survival, progression-free survival, and disease progression; all included longterm follow-up data.
The effect of investigational product on time-to-event end points (overall survival, progression-free survival, disease progression, adverse events, and transfusions) was characterized using Cox proportional hazards models stratified by study protocol. The first occurrence of an event was used in these analyses. The impact of baseline hemoglobin on the treatment effect of DA was characterized by estimating HRs for baseline hemoglobin subgroups (Ͻ 9 g/dL, Ն 9 to 10 g/dL, Ն 10 to 11 g/dL, Ն 11 to 12 g/dL, and Ն 12 g/dL).
Analyses were done to examine whether achieving hemoglobin more than 12 g/dL or more than 13 g/dL, an increase in hemoglobin more than 1 g/dL in 14 days or more than 2 g/dL in 28 days, or receipt of one or more transfusions were associated with an increased risk of death, disease progression, or thromboembolic events. The impact of each factor was assessed individually as a time-dependent covariate in a Cox proportional hazards model; HRs (with 95% CIs) were calculated. Analyses were performed for patients receiving DA and placebo separately. Analyses examining the impact of transfusions on hemoglobin were also performed. The meta-analyses were examined for heterogeneity using Cochrane's Q and the I 2 statistic. If evidence of heterogeneity existed, it was noted in the Results, and further analyses were conducted that assumed the effects being estimated in the different studies are not identical. The Cox models were examined for proportional hazards and any significant departures noted. Baseline imbalances were adjusted for multivariate models, and results are presented if estimated treatment effects differed meaningfully from the univariate models.
The difference in the incidence of adverse events (DA minus placebo) was calculated with 95% CIs.
The incidence of transfusions (with 95% CI) between week 5 and the end of treatment period was calculated by baseline hemoglobin category for each treatment group.
RESULTS
This integrated analysis included data from six randomized, doubleblind, placebo-controlled trials in CIA conducted in 2,122 patients receiving DA (n ϭ 1,200) or placebo (n ϭ 912; Table 1 Fig 1. Kaplan-Meier curves of (A) overall survival, (B) progression-free survival, and (C) disease progression, all including longterm follow-up. Kaplan-Meier curves combined all patients without stratification by study protocol. HR, hazard ratio; DA, darbepoetin alfa.
overall survival in the DA group (estimated relative risk ϭ 1.36; 95% CI, 1.02-1.82).
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Demographics and Baseline Characteristics
Most patients were white, mean age was similar in both groups, and the proportion of women was higher in the DA group. A higher proportion of patients in the placebo group received platinumcontaining chemotherapy (Table 2) .
The most frequent primary tumor types were lung and hematologic cancers, reflecting the three large, phase III studies 10, 12, 22 conducted in these patient populations (Table 2 ). These tumor types accounted for 65% of patients in the DA group and 79% in the placebo group. Most patients had later-stage disease, defined as stage III or higher/extensive. Eastern Cooperative Oncology Group performance status, baseline hemoglobin concentration, and baseline erythropoietin were generally well balanced between the two groups ( Table 2) .
Effect of DA Versus Placebo on Safety Outcomes
Survival and disease progression. For overall survival, progressionfree survival, and disease progression (all including long-term followup), the Kaplan-Meier curves for DA and placebo nearly overlap, with HR of 0.97 (95% CI, 0.85 to 1.1) for overall survival, 0.93 (95% CI, 0.84 to 1.04) for progression-free survival, and 0.92 (95% CI, 0.82 to 1.03) for disease progression (Fig 1) .
Adverse events on study. The HR of on-study deaths suggested a slightly higher risk for death in the DA versus placebo group; however, the 95% CI spanned unity (HR ϭ 1.11; 95% CI, 0.84 to 1.47; Table 3 ). The risk of having a cardiovascular/thromboembolic event was higher for DA compared with placebo (HR ϭ 1.26; 95% CI, 1.00 to 1.59), primarily as a result of the higher incidence of thromboembolic events in the DA group (8% v 5% in placebo; HR ϭ 1.57; 95% CI, 1.10 to 2.26; Table 3 ). Myocardial infarction/coronary artery disease was also reported at a higher rate in the DA group; however, the percentage of patients was low and the CI for the HR was wide (Table 3 ). The incidence of cardiovascular events such as arrhythmia, cerebrovascular accident, and congestive heart failure was similar in both groups (Table 3) .
Effect of Baseline Hemoglobin on Safety Outcomes
DA did not increase mortality and had no effect on progressionfree survival irrespective of baseline hemoglobin concentration-the 95% CIs spanned unity (Figs 2A and 2B) . The expected increased risk of thromboembolic events associated with DA showed a tendency toward an association with baseline hemoglobin (Fig 2C) .
Effect of Rate of Hemoglobin Achieved, Hemoglobin Increase, and Receipt of Transfusions on Safety Outcomes
Not only DA but also transfusions could potentially influence the percentage of patients achieving hemoglobin concentrations more than 12 g/dL or more than 13 g/dL. Therefore, an exploratory investigation of the effect of transfusions on these hemoglobin levels was performed. The percentage of patients who achieved hemoglobin more than 12 g/dL or more than 13 g/dL was only slightly higher in the presence versus absence of transfusions: 37.8% versus 35.6% for DA; 15.8% versus 13.8% for placebo. Likewise, only small differences were observed for patients who achieved hemoglobin more than 13 g/dL: 62.4% versus 57.6% for DA; 40.8% versus 33.7% for placebo. Because transfusions had little impact on hemoglobin more than 12 g/dL or more than 13 g/dL, all hemoglobin values were used to evaluate the effect of hemoglobin achieved on adverse outcomes. Overall survival and progression-free survival seemed to be better in patients who achieved hemoglobin more than 12 g/dL or more than 13 g/dL as compared with those who did not (Fig 3A) . There was no clear relationship between risk for embolism/thrombosis and achievement of hemoglobin more than 12 g/dL or more than 13 g/dL.
We also investigated the effect of transfusions on rates of hemoglobin increase. In the absence of transfusions, the percentage of patients with a more than 1 g/dL in 14 days or more than 2 g/dL in 28 days increase in hemoglobin was 68.8% for DA and 52.3% for placebo or 39.1% for DA and 19.2% for placebo, respectively. When only hemoglobin values due to transfusions were included in the analysis, the percentage of patients with a more than 1 g/dL in 14 days or more than 2 g/dL in 28 days increase in hemoglobin was similar in both treatment groups (86.7% for DA, 87.5% for placebo; or 77.6% for DA, 75.3% for placebo, respectively). Therefore, we investigated the effect of hemoglobin rates of increase resulting from transfusions versus those not resulting from transfusions on adverse outcomes. A more than 1 g/dL in 14 days or more than 2 g/dL in 28 days increase in hemoglobin resulting from transfusions was associated with an increased risk of death and disease progression (Figs 3B and 3C ). When transfusions were excluded from the analysis, these rates of hemoglobin increase were not associated with an increased risk for death or disease progression ( Figs 3B and 3C ). Again, there was no clear association between the risk for embolism/thrombosis and rate of hemoglobin increase in the presence or absence of transfusions ( Figs 3B and 3C ).
Transfusions were associated with a greater risk for death and disease progression in both treatment groups and with a greater risk for embolism/thrombosis in the DA group (Fig 3D) .
Effect of Baseline Hemoglobin on Transfusions
Reductions in the risk of receiving one or more transfusions from week 5 to the end of treatment period were observed for DA relative to placebo, overall and in each baseline hemoglobin category (Appendix Fig A1, online only) . As expected, the incidence of transfusions in patients who initiated DA treatment at baseline hemoglobin 10 to 11 g/dL (19%) was less than half the incidence observed in patients with baseline hemoglobin less than 9 g/dL (41%; Appendix Fig A1,  online only) .
DISCUSSION
Results of some clinical studies in patients with cancer have raised concerns regarding a potential relationship between ESAs and increased risk of mortality and/or disease control. These negative safety 32,33 It should also be noted that a recently published study-level meta-analysis 27 and a recent abstract on a patient-level meta-analysis 33a have reported a negative impact of ESA use on survival in cancer patients.
In this analysis of pooled individual data from patients with CIA, we did not detect increased mortality or increased disease progression with administration of DA. Likewise, a number of study-level metaanalyses of patients with cancer did not show a clear effect of ESAs on mortality or disease progression in those patients who received chemotherapy. [13] [14] [15] [16] Notably, those meta-analyses included trials conducted both within and outside the currently approved label.
Of the studies of ESA use in patients with cancer that resulted in negative safety outcomes, three studies initiated ESA therapy at relatively high baseline hemoglobin levels, 19, 21, 25 and one study noted poorer outcomes in patients with baseline hemoglobin more than 11 g/dL.
18 These observations have lead to speculation that high baseline hemoglobin may contribute to adverse outcomes. In the present analysis and in two large, study-level meta-analyses, 13, 14 however, there was no effect of baseline hemoglobin on mortality and/or disease progression in patients with cancer treated with ESAs.
It has also been suggested that high hemoglobin targets lead to negative safety outcomes: six of the trials with safety concerns targeted hemoglobin levels greater than the current upper safety limit of 12 g/dL.
18,19, 21, 22, 24, 25 In the present study, there was no increased risk of death or disease progression among patients who achieved hemoglobin more than 12 or more than 13 g/dL or among patients not receiving transfusions who had rates of hemoglobin increase more than 1 g/dL in 14 days or more than 2 g/dL in 28 days. Patients' ability to achieve higher hemoglobin levels or increases in hemoglobin more than 1 g/dL in 14 days or more than 2 g/dL in 28 days may be reflective of a better biologic subgroup; therefore, this analysis may be confounded with responsiveness to treatment. Given these findings, we speculate that the negative safety signals observed in trials with high target hemoglobins may be attributed, in part, to patients who do not respond to ESAs. Future clinical trials to investigate whether failure to achieve the target hemoglobin level contributes to greater mortality would be informative.
Of note, transfusions and rates of hemoglobin increase due to transfusions were associated with increased risk of mortality and disease progression among patients treated with either DA or placebo. These negative outcomes may be confounded by the underlying health of the patients, since a requirement for transfusions may indicate poorer health. Thus, causality cannot be determined in this kind of analysis. Interestingly, an increased risk for death in patients receiving preoperative blood transfusions has been observed in a recent meta-analysis. 34 Because the relationship between adverse outcomes and transfusions in patients with an increase in hemoglobin is a clinically relevant issue, further research in this area is warranted.
Research has demonstrated that patients with cancer are at a higher risk for thrombotic events relative to individuals without cancer. 35, 36 In our analysis, DA increased the absolute risk for thromboembolic events from 5% to 8% (57% relative risk), which is slightly lower than the 67% to 68% increased relative risk observed in two large study-level meta-analyses of ESAs in patients with cancer (both meta-analyses noted that the potential thrombophilic properties of ESAs are dependent on the underlying risk for thromboembolic complications). 13, 14 In concordance with the meta-analysis conducted by Seidenfeld et al (2006) , 14 the expected increased risk for thromboembolic events in our analysis did not seem to be strongly associated with baseline hemoglobin, and there was no clear effect of achieved hemoglobin levels. Likewise, there seemed to be no increased risk resulting from rates of hemoglobin increase more than 1 g/dL in 14 days or more than 2 g/dL in 28 days. However, to reduce the risk for thromboembolic events, health care providers should use the lowest dose of ESAs that will gradually increase hemoglobin to a level that will avoid the need for transfusions, as stated in the prescribing information.
28,29
The increased risk of cardiovascular/thromboembolic events in oncology patients receiving ESAs might explain the increases in mortality associated with ESAs observed in several studies with nonanemic patients and/or those that targeted high hemoglobin concentrations. 19, 20, 24 However, although increases in thromboembolic events have been observed almost uniformly across clinical trials and metaanalyses, adverse effects on survival have not. Thus other unknown factors, in addition to the known risk of thromboembolic events, may be contributing to the observed adverse outcomes in those studies.
The present analysis reaffirmed the benefit of ESAs in reducing the risk of receiving a transfusion. Overall, patients treated with DA had a 54% lower risk of transfusions than patients treated with placebo. As expected, the absolute risk was dependent on baseline hemoglobin: HR was 0.50 at Ն 9 to 10 g/dL and 0.32 at Ն 12 g/dL. Similarly, a meta-analysis of studies that compared early intervention (generally, initiation of therapy Ͻ 11 g/dL) versus late intervention (generally, initiation of therapy when hemoglobin level decreases to Ͻ 10 g/dL) with ESA use demonstrated an approximate 50% reduction in the risk of transfusion favoring the early intervention approach.
37 Also, a meta-analysis of 42 trials with 6,510 patients showed more of a reduction in the RR for transfusion in ESA-treated patients when treatment was initiated at hemoglobin 10 to 12 g/dL versus less than 10 g/dL (RR ϭ 0.46, 95% CI, 0.40 to 0.53; v RR ϭ 0.70, 95% CI, 0.65 to 0.70). 13 Avoidance of transfusion is an important clinical benefit provided by ESAs; use of transfusions to relieve the symptoms of anemia carries inherent risks, which have been well documented, 38-40 and transfusions are also disruptive for patients, caregivers, and physicians.
In summary, many clinical trials that evaluated ESAs for the treatment of CIA did not negatively impact survival or increase adverse cancer outcomes and provided significant health benefits by reducing transfusion requirements. Further support for these observations is provided in the present analysis. We acknowledge that our results are not applicable to the general population and do not negate the negative safety signals observed in some trials of ESAs in patients with cancer, most of which were conducted outside the approved indication; however, the lack of a clear effect of ESAs on the risk of death or disease progression in this analysis indicates that further research is needed to answer this question.
